Clinical Trial Update: Extension Study of ABP-671 in Participants With Gout [Phase 2, Phase 3]

View source ↗

Summary

An extension study of ABP-671 for gout has been terminated (Phase 2/Phase 3). The update does not provide further results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• ABP-671

Snippet

Sponsor: Atom Therapeutics Co., Ltd | Conditions: Gout | Phase 2, Phase 3 | Status: TERMINATED